Genomic analysis of germline and somatic lesions at the FCGR locus; from reference genomes to clinicobiological implications
- Published on: June 19 2020
)
Monoclonal antibody (mAb) immunotherapy is becoming standard in the treatment of cancer, particularly for B-cell lymphoma patients. However responses are variable and relapse is common, thus the molecular mechanisms that underpin resistance need to be defined. mAbs interact with the Fc gamma receptors (FcγRs), a family of cell surface molecules crucial in the immune response. Human cells express six FcγRs: the high-affinity FcγRI and 5 low-affinity receptors which have both activatory (FcγRIIa, FcγRIIc, FcγRIIIa and FcγRIIIb) and inhibitory (FcγRIIb) capabilities.
